Sermorelin research: mechanism, trials, and pharmacokinetics

Start here

This page reads the sermorelin research record one study at a time. The short version: sermorelin works by acting on the pituitary gland rather than by adding growth hormone directly, and the cleanest human evidence is in children with a diagnosed growth-hormone shortage ^[1] and in short controlled studies of older men ^[2]. The mechanism is well understood; the pharmacokinetics are well characterized ^[3]; the long-term adult anti-aging data are not ^[5].

Below, each major finding gets its own section. Technical terms are glossed on first use, but the depth stays — this is the full trial record, not a summary of it. Where a finding comes from a closely related analog rather than sermorelin itself, that is stated plainly so nothing is over-credited to sermorelin.

What is sermorelin, and how the sermorelin peptide works

What is sermorelin? It is the amidated 29-amino-acid amino-terminal fragment of GHRH — the body's growth hormone-releasing hormone — and the shortest fragment that retains full activity at the GHRH receptor ^[6]. The sermorelin peptide binds GHRH receptors (a class B G-protein-coupled receptor) on anterior-pituitary somatotrophs, the gland's growth-hormone-making cells, and activates the Gs/adenylate cyclase/cAMP/PKA pathway — the internal relay that turns the receptor signal into action — driving GH gene transcription and pulsatile GH release ^[6].

Because sermorelin acts upstream on the pituitary rather than supplying growth hormone from outside, the natural negative-feedback loops through somatostatin (the opposing "brake" hormone) and IGF-1 stay intact, preserving the body's normal pulsatile GH pattern ^[6]. A 2025 Nature Reviews Endocrinology review synthesizes this biology across GHRH-receptor signaling, the GH/IGF-1 axis, and the therapeutic landscape of GHRH agonists and antagonists ^[6].

Does sermorelin work: the human efficacy record

Does sermorelin work? In its approved historical indication, yes — the pediatric data are clear. In a multicenter trial of prepubertal growth-hormone-deficient children, once-daily subcutaneous GHRH(1-29) accelerated linear growth, raising first-year height velocity from about 4.1 cm/year to roughly 7-8 cm/year, without excessive IGF-1 generation ^[1].

In healthy older men (mean 68 years), subcutaneous GHRH(1-29) at 0.5 mg and 1 mg twice daily for 14 days produced dose-related increases in 24-hour GH and IGF-1; after the high-dose course, GH/IGF-1 parameters no longer differed from those of young men, with no effect on fasting glucose ^[2]. GHRH(1-29) was also studied for radiation-induced GH deficiency after cranial irradiation ^[12]. For adult anti-aging and body-composition goals, the long-term efficacy record is limited and the cautionary editorial stands ^[5].

Sermorelin pharmacokinetics

In 30 healthy men, intravenous GHRH(1-29)NH2 elicited significant GH release at doses as low as 0.25 mcg/kg, with maximal release at 1-2 mcg/kg; despite rapid plasma elimination, GH remained elevated for about 3 hours, while intranasal bioavailability was only 3-5% ^[3]. The native peptide's short plasma half-life — on the order of ~10-12 minutes after intravenous administration — is why GHRH(1-29) is given by injection and why longer-acting analogs were developed (D-Ala2 substitution, and the albumin-binding DAC technology behind a multi-day GHRH analog) ^[3]. The low intranasal figure is the mechanistic basis for skepticism about oral and sublingual products, covered on the sermorelin tablets page.

Sermorelin vs ipamorelin and sermorelin vs tesamorelin

Sermorelin vs ipamorelin: these act by different mechanisms. Sermorelin is a GHRH analog that works at the GHRH receptor ^[6]; ipamorelin is a growth-hormone-releasing peptide that works at the separate ghrelin/GHS receptor. They are different receptor families, often discussed together because both are GH secretagogues, but they are not interchangeable.

Sermorelin vs tesamorelin: both are GHRH-pathway molecules, but tesamorelin is a stabilized, longer-acting synthetic GHRH analog studied in body-composition and cognition research; in a 20-week randomized controlled trial in 152 older adults, daily subcutaneous tesamorelin (1 mg before bedtime) had a favorable effect on cognition (P=0.03), raised IGF-1 by 117% within the physiologic range, and reduced percent body fat by 7.4% ^[7]. Sermorelin is the short-acting native fragment; tesamorelin is the stabilized analog. An editorial argues sermorelin's preserved pulsatility and feedback may be a more physiologic approach to adult GH insufficiency than recombinant growth hormone ^[4].